Clinical trials: NERVES
Breast Cancer Female, Pain, Postoperative
Analgesic Effect of Adding Thoracic Paravertebral Nerve Blocks to Modified PEC Block in Breast Cancer Surgery
To compare efficacy and safety of adding thoracic paravertebral nerve blocks to modified PEC block versus modified PEC block only in breast cancer surgery.
- Trial name
- NCT04056676
- Testing
- Thoracic paravertebral block under ultrasound guidance, Intraoperative modified PEC block, GA with ETT
- Where
- Thailand
- Volunteers
- 100 people
- Sponsor
- Mahidol University
Postoperative Ileus
Anti-inflammatory Effect of Pre-operative Stimulation of the Cholinergic Anti-Inflammatory Pathway
Hypothesis: Prucalopride can mimic electrical stimulation of the abdominal vagus nerve and has an anti-inflammatory effect. Aims: In the present pilot study, the investigators want to evaluate the anti-inflammatory effect of…
- Trial name
- NCT02425774
- Testing
- Vagus stimulation, Prucalopride
- Where
- Belgium
- Volunteers
- 31 people
- Sponsor
- KU Leuven
Pain, Shoulder Injury
Efficacy of Nerve Blockade Performed Prior to Surgical Intervention Versus Following Surgical Intervention
Nerve blocks, or pain medication injected next to the nerve while patients are asleep, are commonly used for pain management after shoulder surgery and are considered highly effective in decreasing post-operative pain.
- Trial name
- NCT02666118
- Testing
- Preemptive Interscalene Block - Single Shot, Postoperative Interscalene Block- Single Shot, Preemptive Interscalene Block - Catheter
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)
This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children with newly diagnosed DIPG or DMG. All patients will receive BXQ-350 by intravenous (IV) infusion and radiation therapy.
- Trial name
- KONQUER (NCT04771897)
- Testing
- BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance, BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Carcinoma, Glioblastoma
MRinRT: Swansea University and SWWCC Collaboration Study.
The aim of this study is to learn whether using MRI (magnetic resonance imaging) scans to plan radiotherapy is better than using CT (computed tomography) scans alone.
- Conditions
- Carcinoma, Glioblastoma, Radiotherapy, MRI
- Trial name
- MRinRT (NCT07365124)
- Testing
- MRI
- Where
- United Kingdom
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Swansea Bay University Health Board
Metastatic Melanoma
Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma
Purpose of investigation: Primary hypotheses: Immunization of patients with 4 melanoma antigen peptides will induce augmented specific IFN-y-producing CD8+ T cells against all 4 antigens simultaneously.
- Trial name
- NCT00203879
- Testing
- MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug), MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Chicago
Malignant Glioma
AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma
The trial will address safety and tolerability of the combination of the IDH1R132H-specific vaccine with checkpoint blockade and seeks to explore predictive biomarkers for response to checkpoint blockade in post-treatment tumor…
- Trial name
- AMPLIFY-NEOVAC (NCT03893903)
- Testing
- IDH1R132H peptide vaccine, Avelumab
- Where
- 10 sites in Germany
- Volunteers
- 69 people
- Sponsor
- German Cancer Research Center
Melanoma
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
The purpose of this study is to investigate the pharmacokinetics (PK) similarity of Bmab1700 (an intended nivolumab biosimilar), compared with United States (US)-licensed Opdivo, in participants after complete surgical removal of…
- Trial name
- NCT07476326
- Testing
- Bmab1700, Opdivo
- Where
- 46 sites in Brazil, Chile and 8 more
- Volunteers
- 120 people
- Sponsor
- Biocon Biologics UK PLC
Relapsing-remitting Multiple Sclerosis
Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
Hypothesis: Sunphenon, a green tea extract containing 95% egcg, given daily as oral medication over a period of 18 months has anti-inflammatory and neuroprotective properties in patients with relapsing-remitting multiple…
- Trial name
- SuniMS (NCT00525668)
- Testing
- epigallocatechin-gallate (Sunphenon)
- Where
- 2 sites in Germany
- Volunteers
- 120 people
- Sponsor
- Charite University, Berlin, Germany
Diabetes Mellitus, Type 2, Cognitive Dysfunction
Detection of Visual-Auditory Reaction Rates in Individuals With Type 2 Diabetes
Background: The primary purpose of our study was to understand the damage in the peripheral nerves of patients with diabetes and to determine the change in patients' reaction rates and perceptions by the age groups, duration of…
- Conditions
- Diabetes Mellitus, Type 2, Cognitive Dysfunction, Nerve Damage
- Trial name
- NCT05725889
- Testing
- recation time test
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Baskent University
Brain and Central Nervous System Tumors
ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of glioblastoma multiforme.
- Trial name
- NCT00016991
- Testing
- gefitinib
- Where
- United States
- Sponsor
- Duke University
Giant Axonal Neuropathy (GAN)
Intraneural Administration of scAAV9/JeT-GAN Into the Vagus Nerve for Patients With Giant Axonal Neuropathy (GAN)
Giant axonal neuropathy (GAN) is a rare pediatric disorder caused by autosomal recessive mutations in the GAN gene. GAN is a multisystem, neurodegenerative disorder affecting the peripheral nervous system (PNS), central nervous…
- Trial name
- NCT07543991
- Testing
- scAAV9/JeT-GAN
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Texas Southwestern Medical Center
Pudendal Neuralgia, Canal Syndrome
Therapeutic Effects Analysis of Pudendal Nerve Infiltrations After 3 Months, in Patients Suffering of Pudendal Neuralgia
Pudendal neuralgia is a recent identified pathology, extremely invalidating, related to chronic pelvic entrapment. Nowadays, pudendal neuralgia can be treated with: neuropathic pains treatment specific kinesitherapy Alcock's…
- Trial name
- INFILTHERA (NCT00851513)
- Testing
- Lidocaine, Depmedrol, physiological serum
- Where
- 9 sites in France
- Volunteers
- 202 people
- Sponsor
- Nantes University Hospital
Vestibular Diseases, Vestibular Neuronitis
Acute Unilateral Vestibulopathy and Corticosteroid Treatment
Randomized placebo controlled trial on patients suffering from acute unilateral vestibulopathy. Patients will be randomized into 3 arms; 1) Placebo only, 2) Short corticosteroid treatment (3days) 3) Longer corticosteroid…
- Trial name
- NCT02912182
- Testing
- Betamethasone, Prednisolone
- Where
- 3 sites in Sweden
- Volunteers
- 78 people
- Sponsor
- Lund University
Multiple Sclerosis, NMO Spectrum Disorder
Tongji NADs Cohort
Neurological Autoimmune Diseases (NADs) are disorders caused by abnormal immune system attacks on neural tissues, affecting multiple systems including the central nervous system, peripheral nervous system, and neuromuscular…
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Autoimmune Encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
- Trial name
- NCT07333196
- Testing
- No active interventions
- Where
- China
- Volunteers
- 1,550 people
- Sponsor
- Tongji Hospital
Neuroma, Neuropathic Pain
Pain Outcomes After Digital Amputation Using Tulavi Allay™ Nerve Cap
In 2016, one in five individuals in the United States (US) experienced chronic pain, and approximately 40% of them suffered from neuropathic pain.
- Trial name
- NCT06915662
- Testing
- Tulavi allay Nerve Cap
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Brain Metastases, Glioma of Brain
Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases
Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) is a potentially powerful diagnostic tool for the management of brain cancer and other conditions in which the blood-brain barrier is compromised.
- Conditions
- Brain Metastases, Glioma of Brain, Brain Tumor, Metastatic Melanoma
- Trial name
- NCT03698162
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Bevacizumab Injection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Southern California
Melanoma (Skin)
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003346
- Testing
- acetaminophen, acetylcysteine, carmustine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Merkel Cell Carcinoma
Targeted Therapy and Avelumab in Merkel Cell Carcinoma
10.17 GoTHAM is intended as a signal-seeking, biomarker, phase Ib/II study that will evaluate the safety and anti-tumour activities of the novel combination of avelumab with 177-Lu-DOTATATE (a type of peptide receptor…
- Trial name
- GoTHAM (NCT04261855)
- Testing
- Avelumab, External Beam Radiation Therapy (EBRT), Lutetium-177 (177Lu)-DOTATATE
- Where
- 10 sites in Australia
- Volunteers
- 19 people
- Sponsor
- Melanoma and Skin Cancer Trials Limited
Melanoma, Breast Cancer
Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)
Coxsackie A21 (CVA21) virus is to be administered by IV infusion to patients with Stage 4 melanoma, prostate and breast cancer. This is a dose escalation, safety study.
- Conditions
- Melanoma, Breast Cancer, Prostate Cancer
- Trial name
- PSX-X04 (NCT00636558)
- Testing
- CVA21
- Where
- 2 sites in Australia
- Volunteers
- 8 people
- Sponsor
- Viralytics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.